A phase I/II basket trial to evaluate the efficacy and safety of CEA-targeted CAR-T cells is recruiting patients with relapse/refractory CEA+ tumors including liver cancer (NCT04348643). This evidence concerns the gene CEACAM5 and liver cancer.